4.6 Article

Estrogen and COVID-19 symptoms: Associations in women from the COVID Symptom Study

Journal

PLOS ONE
Volume 16, Issue 9, Pages -

Publisher

PUBLIC LIBRARY SCIENCE
DOI: 10.1371/journal.pone.0257051

Keywords

-

Funding

  1. Wellcome Trust
  2. MRC/BHF
  3. Alzheimer's Society
  4. EU
  5. NIHR
  6. CDRF
  7. ESRC
  8. European Community's Seventh Framework Programme (FP7/2007-2013)
  9. National Institute for Health Research (NIHR)
  10. UK Economic and Social Research Council [ES/N000404/1]
  11. NIHR Doctoral Fellowship [NIHR300159]
  12. ESRC [ES/N000404/1] Funding Source: UKRI
  13. National Institutes of Health Research (NIHR) [NIHR300159] Funding Source: National Institutes of Health Research (NIHR)

Ask authors/readers for more resources

The study found that menopausal women had higher rates of predicted COVID-19, while users of combined oral contraceptive pills had lower rates. Hormone replacement therapy usage did not consistently show associations with COVID-19. However, caution should be taken when interpreting the results due to certain limitations in the data collection.
It has been widely observed that adult men of all ages are at higher risk of developing serious complications from COVID-19 when compared with women. This study aimed to investigate the association of COVID-19 positivity and severity with estrogen exposure in women, in a population based matched cohort study of female users of the COVID Symptom Study application in the UK. Analyses included 152,637 women for menopausal status, 295,689 women for exogenous estrogen intake in the form of the combined oral contraceptive pill (COCP), and 151,193 menopausal women for hormone replacement therapy (HRT). Data were collected using the COVID Symptom Study in May-June 2020. Analyses investigated associations between predicted or tested COVID-19 status and menopausal status, COCP use, and HRT use, adjusting for age, smoking and BMI, with follow-up age sensitivity analysis, and validation in a subset of participants from the TwinsUK cohort. Menopausal women had higher rates of predicted COVID-19 (P = 0.003). COCP-users had lower rates of predicted COVID-19 (P = 8.03E-05), with reduction in hospital attendance (P = 0.023). Menopausal women using HRT or hormonal therapies did not exhibit consistent associations, including increased rates of predicted COVID-19 (P = 2.22E-05) for HRT users alone. The findings support a protective effect of estrogen exposure on COVID-19, based on positive association between predicted COVID-19 with menopausal status, and negative association with COCP use. HRT use was positively associated with COVID-19, but the results should be considered with caution due to lack of data on HRT type, route of administration, duration of treatment, and potential unaccounted for confounders and comorbidities.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.6
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available